ProKidney Corp. (PROK)
$1.47-6.37%Close
SELLCRISIS · day 2
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $218M
- Beta
- 1.80
- P/E (TTM)
- -2.58
- Short % float
- 21.86%
- Days to cover
- 11.0
- SI change
- +10.9%
- 1W
- -6.37%
- 1M
- -15.52%
- vs SPY 1W
- -5.39%
- vs SPY 1M
- -17.38%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
EARNINGS HISTORY
LOADING…Loading earnings…
Company news
FAQ
- What is LOPJLB’s current signal on PROK?
- LOPJLB’s latest quantitative signal on ProKidney Corp. (PROK) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is PROK in?
- ProKidney Corp. (PROK) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does ProKidney Corp. (PROK) do?
- ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments. Their flagship product is Renal Autologous Cell Therapy (RAC-T), a unique cellular admixture derived from a patient's own cells. RAC-T is undergoing significant clinical evaluation; it is concurrently in Phase III and Phase II trials for individuals…